

Cenobamate

Cenobamate is contraindicated in patients with Familial Short-QT syndrome. Please undertake an ECG prior to prescription if this is suspected.

Please prescribe cenobamate as follows:

Week 1	12.5mg once daily
Week 3	25mg once daily
Week 5	50mg once daily
Week 7	100mg once daily
Week 9	150mg once daily
Week 11	200mg once daily

The dose may be increased thereafter by 50mg/day every 2 weeks to a maximum dose of 400mg/day depending on response.

The dose should not be increased any faster than fortnightly. If the patient experiences side effects during titration, the interval between dose increases can be extended.

There is no need for routine plasma level monitoring.

Cenobamate can affect the metabolism of phenytoin and blood monitoring of phenytoin levels may be required during the titration period. Cenobamate can increase phenytoin levels and it is recommended to take baseline phenytoin levels followed by 4 weekly blood levels until dose is titrated.

Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare, potentially life threatening side effect of Cenobamate. Other than a rash, symptoms of DRESS typically include: fever, rash associated with other organ system involvement, lymphadenopathy, liver function test abnormalities and eosinophilia. Early symptoms of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If signs and symptoms suggestive of these reactions appear, cenobamate must be withdrawn immediately.

Cenobamate may cause somnolence, dizziness, fatigue, impaired vision and other CNS-related symptoms. Patients should be advised not to drive or engage in other potentially hazardous activities until it is known whether cenobamate affects their ability to perform these tasks.

Women of child bearing age must use adequate contraception during treatment and until 4 weeks after treatment discontinuation.

Please ensure the same manufacturer/brand is dispensed consistently.

Cenobamate withdrawal

Unless safety concerns require abrupt withdrawal, the drug should be discontinued over at least 2 weeks.